PCL Inc
PCL Inc is a South Korean biotechnology company focused on the development and commercialization of innovative pharmaceutical products, primarily in the areas of oncology and autoimmune diseases.
Business. PCL Inc (241820.KQ) is a biotechnology and medical research company listed on the KOSDAQ exchange. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. Specific details regarding operating segments, headquarters location, and geographic presence are not available in the provided data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
PCL Inc (241820.KQ) is a biotechnology and medical research company listed on the KOSDAQ exchange. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. Specific details regarding operating segments, headquarters location, and geographic presence are not available in the provided data.
PCL Inc's capital structure is characterized by a debt-to-equity ratio of 0.54, indicating a moderate reliance on debt financing. The company holds cash and equivalents of KRW 6,397.8 billion, but this is offset by long-term debt of KRW 19,006.9 billion, resulting in a net cash position that is negative after subtracting total debt. The liquidity risk is rated as medium, with a current ratio of 1.55, suggesting the company has sufficient short-term assets to cover its short-term liabilities.
Profitability metrics for PCL Inc are negative, with a return on equity of -10.15% and a return on assets of -5.79%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The gross profit is negative at KRW -2,747.6 billion, and the operating income is also negative at KRW -3,148.0 billion, reflecting significant operational challenges.
PCL Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risks if market conditions in its primary segment or region deteriorate.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. However, the negative operating cash flow of KRW -4,916.7 billion and free cash flow of KRW -3,122.6 billion suggest that the company is not generating sufficient cash from operations to sustain or grow its business without external financing.
Risk factors for PCL Inc include a medium liquidity risk and a low dilution risk. The company's negative net cash position and significant long-term debt raise concerns about its ability to meet long-term obligations. The dilution risk is low, but the company may need to issue additional shares to fund operations or reduce debt, which could dilute existing shareholders' equity.
Recent events and filings for PCL Inc include a significant net loss of KRW -3,601.3 billion for the period under review. The company has also reported negative operating and free cash flows, indicating ongoing financial stress. No recent transcripts or detailed filings are available to provide further insight into the company's strategic direction or operational performance.
- PCL Inc is experiencing significant financial stress, with negative profitability and cash flow metrics.
- The company's capital structure is moderately leveraged, with a debt-to-equity ratio of 0.54.
- PCL Inc's return on equity and return on assets are both negative, indicating poor performance.
- The company's liquidity position is medium risk, with a current ratio of 1.55.
- PCL Inc's revenue is concentrated in a single segment, increasing its exposure to market-specific risks.
- The company's growth trajectory is uncertain, with no clear signs of improvement in its financial performance.
Bull / Bear case
Generated · model-assistedCash conversion of 1.37 places PCL Inc in the top quartile, exceeding the cohort median of 0.87.
Dilution risk is assessed as low, providing some stability for existing shareholders amidst financial volatility.
The company faces high credit risk, indicating significant concerns regarding its ability to meet financial obligations.
A four-year revenue CAGR of -61.0% demonstrates a persistent and severe long-term decline in top-line growth.
In focus — financials by report
Revenue KRW 46.15B, −14,0% YoY; Operating income −200,3% YoY.
- ▍Revenue KRW 46.15B, −14,0% YoY
- ▍Operating income −200,3% YoY
- ▍Net income −262,3% YoY
- ▍Free cash flow −312,6% YoY
- ▍Net margin -68.6%
Revenue KRW 53.68B; Operating income KRW 25.68B.
- ▍Revenue KRW 53.68B
- ▍Operating income KRW 25.68B
- ▍Net margin 36.3%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- PCL Inc Market data — financials · 2026-05-26